The Potential of Indole Alkaloids in Bone Health and Osteoporosis Management
Source abstract
Abstract
Indole alkaloids, a class of plant-derived nitrogen-containing compounds, have emerged as promising candidates for osteoporosis treatment. Their favorable biocompatibility profile demonstrated efficacy in preclinical models, and low reported toxicity make them attractive alternatives to existing therapies. This review focuses on the therapeutic potential of specific indole alkaloids, including vindoline, rutaecarpine, harmine, and its derivatives, in promoting bone health and managing osteoporosis.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Bone Metabolism and Diseases · Inflammatory mediators and NSAID effects · Microscopic Colitis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Science, University of Basilicata, Viale dell’Ateneo Lucano 10, 85100 Potenza, Italy
U.O.S. Reumatologia, P.O. of Castrovillari, ASP Cosenza, 87012 Castrovillari, Italy
Faculty of Science, Assiut University, Assiut 71516, Egypt
Faculty of Pharmacy, Sphinx University, New Assiut 71515, Egypt
References (85)
Show source-provided references
1. Consensus development conference. Diagnosis, prophylaxis and treatment of osteoporosis10.1016/0002-9343(91)90512-V ↗
2. Diagnosis, prophylaxis, and treatment of osteoporosis
3. WHO Study Group on Assessment of Fracture Risk & Its Application to Screening for Postmenopausal Osteoporosis (1994). Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis, World Health Organization.
4. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Synopsis of a WHO Report10.1007/BF01622200 ↗
5. Gueldner, S.H., Grabo, T.N., Newman, E.D., and Cooper, D.R. (2007). Osteoporosis: Clinical Guidelines for Prevention, Diagnosis, and Management, Springer Publishing Company.
6. Melton, L.J. (1999). Epidemiology of fractures. Osteoporosis in Men, Academic Press.10.1016/B978-012528640-4/50002-2 ↗
7. Meta-analysis of how well measures of bone mineral density predict occurence of osteoporotic fractures10.1136/bmj.312.7041.1254 ↗
8. Risk factors for hip fracture in white women10.1056/NEJM199503233321202 ↗
9. Spine fracture risk is predicted by nonspine fractures10.1007/BF02352253 ↗
10. Spatial relationships between prevalent and incident spine fractures10.1016/S8756-3282(98)00176-8 ↗
11. Patients with prior fractures have an increased risk of future fractures: A summary of the literature and statistical synthesis10.1359/jbmr.2000.15.4.721 ↗
12. Bone mineral density in children and adolescent females treated with high doses of L-thyroxine10.1159/000182712 ↗
13. The effect of thyroid hormone on skeletal integrity10.7326/0003-4819-130-9-199905040-00016 ↗
14. Marcus, R., Feldman, D., and Kelsey, J. (1997). Osteoporosis, Academic Press, Inc.
15. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry10.1016/S0002-9378(94)70299-3 ↗
16. Warfarin use and risk for osteoporosis in elderly women. Study of Osteoporotic Fractures Research Group10.7326/0003-4819-128-10-199805150-00006 ↗
17. Normal cortical bone mass in patients after long term coumadin therapy10.1210/jcem-54-2-470 ↗
18. The role of testosterone in cyclosporine-induced osteopenia10.1359/jbmr.1997.12.4.607 ↗
19. Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation10.1046/j.1365-2362.1996.00170.x ↗
20. Effects of three immunosuppressive regimens on vertebral bone density in renal transplant recipients: A prospective study10.1097/00007890-199702150-00009 ↗
21. Reduced bone mineral density in HIV-positive individuals10.1097/00002030-200109070-00019 ↗
22. BMD is reduced in HIV-infected men irrespective of treatment10.1359/JBMR.0301246 ↗
23. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis10.1056/NEJM199502023320506 ↗
24. Castrated men show bone loss: Effect of calcitonin treatment on biochemical indices of bone remodelling10.1210/jcem-69-3-523 ↗
25. Expression of membrane-bound and soluble receptor activator of NF-kappaB ligand (RANKL) in human T cells10.1016/j.imlet.2004.05.010 ↗
26. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women10.1172/JCI200317215 ↗
27. Correlates of osteoprotegerin levels in women and men10.1007/s001980200045 ↗
28. The role of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption10.1359/jbmr.2000.15.1.2 ↗
29. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation10.1016/S0092-8674(01)00622-5 ↗
30. Osteoporos10.1016/S0140-6736(06)68891-0 ↗
31. Interim report and recommendations of the World Health Organization task-force for osteoporosis10.1007/s001980050224 ↗
32. Consensus development conference. Diagnosis, prophylaxis, and treatment of osteoporosis10.1016/0002-9343(93)90218-E ↗
33. Risk factors for longitudinal bone loss in elderly men and women: The Framingham Osteoporosis Study10.1359/jbmr.2000.15.4.710 ↗
34. Screening for osteoporosis10.7326/0003-4819-112-7-516 ↗
35. AACE/ACE Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2020 update: Risk stratification and intervention thresholds10.1016/j.eprac.2021.01.019 ↗
36. Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline from the American College of Physicians10.7326/M22-1034 ↗
37. Romosozumab treatment in postmenopausal women with osteoporosis10.1056/NEJMoa1607948 ↗
38. FRAME: Study: The foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab10.1002/jbmr.3427 ↗
39. Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: A randomized, double-blind, phase 2, parallel-group study10.1002/jbmr.3452 ↗
40. Parathyroid hormone and parathyroid hormone-related protein analogs in osteoporosis therapy10.1007/s11914-017-0353-4 ↗
41. Lin, B., Xu, P., Zheng, J., Deng, X., Ye, Q., Huang, Z., and Wang, N. (2022). Effects and mechanisms of natural alkaloids for prevention and treatment of osteoporosis. Front. Pharmacol., 13.10.3389/fphar.2022.1014173 ↗
42. Oxidative stress and production of bioactive monoterpene indole alkaloids: Biotechnological implications10.1007/s10529-013-1348-6 ↗
43. New molecules modulating bone metabolism-new perspectives in the treatment of osteoporosis10.33549/physiolres.933720 ↗
44. Antiproliferative activity of some 1,4-dimethylcarbazoles on cells that express estrogen receptors: Part I10.3109/14756366.2011.603132 ↗
45. Synthesis and evaluation of cytotoxic activities of new guanidines derived from carbazoles10.1016/j.bmcl.2013.12.047 ↗
46. New trimethoxybenzamides and trimethoxyphenylureas derived from dimethylcarbazole as cytotoxic agents. Part I10.1002/jhet.1951 ↗
47. N-alkyl carbazole derivatives as new tools for Alzheimer’s disease: Preliminary studies10.3390/molecules19079307 ↗
48. Crystallographic study and biological evaluation of 1,4-dimethyl-N-alkylcarbazoles10.2174/1568026615666150317222444 ↗
49. Saturnino, C., Grande, F., Aquaro, S., Caruso, A., Iacopetta, D., Bonomo, M.G., Longo, P., Schols, D., and Sinicropi, M.S. (2018). Chloro-1,4-dimethyl-9 H-carbazole derivatives displaying anti-HIV activity. Molecules, 23.10.3390/molecules23020286 ↗
50. Grande, F., De Bartolo, A., Occhiuzzi, M., Caruso, A., Rocca, C., Pasqua, T., Carocci, A., Rago, V., Angelone, T., and Sinicropi, M.S. (2021). Carbazole and Simplified Derivatives: Novel Tools toward β-Adrenergic Receptors Targeting. Appl. Sci., 11.10.3390/app11125486 ↗
51. Caruso, A., Barbarossa, A., Carocci, A., Salzano, G., Sinicropi, M., and Saturnino, C. (2021). Carbazole Derivatives as STAT Inhibitors: An Overview. Appl. Sci., 11.10.3390/app11136192 ↗
52. Bonomo, M., Caruso, A., El-Kashef, H., Salzano, G., Sinicropi, M., and Saturnino, C. (2023). An Update of Carbazole Treatment Strat-egies for COVID-19 Infection. Appl. Sci., 13.10.3390/app13031522 ↗
53. Sinicropi, M.S., Tavani, C., Rosano, C., Ceramella, J., Iacopetta, D., Barbarossa, A., Bianchi, L., Benzi, A., Maccagno, M., and Ponassi, M. (2021). A Nitrocarbazole as a New Microtubule-Targeting Agent in Breast Cancer Treatment. Appl. Sci., 11.10.3390/app11199139 ↗
54. Grande, F., Ioele, G., Caruso, A., Occhiuzzi, M., El-Kashef, H., Saturnino, C., and Sinicropi, M. (2023). Carbazoles: Role and Functions in Fighting Diabetes. Appl. Sci., 13.10.3390/app13010349 ↗
55. Indoles as therapeutics of interest in medicinal chemistry: Bird’s eye view10.1016/j.ejmech.2017.04.003 ↗
56. Yang, K., Li, J., and Tao, L. (2022). Purine metabolism in the development of osteoporosis. Biomed. Pharmacother., 155.10.1016/j.biopha.2022.113784 ↗
57. Anti-osteoclastogenic effects of indole alkaloids isolated from barley (Hordeum vulgare Var. Hexastichon) grass10.1021/acs.jafc.1c04337 ↗
58. Bone loss in inflammatory disorders10.1677/JOE-08-0568 ↗
59. Antihyperglycemic activity of Catharanthus roseus leaf powder in streptozotocin-induced diabetic rats10.4103/0974-8490.65523 ↗
60. Goboza, M., Aboua, Y.G., Chegou, N., and Oguntibeju, O.O. (2019). Vindoline effectively ameliorated diabetes-induced hepatotoxicity by docking oxidative stress, inflammation and hypertriglyceridemia in type 2 diabetes-induced male Wistar rats. BioMed. Pharmacother., 112.10.1016/j.biopha.2019.108638 ↗
61. Zhan, Y., Liang, J., Tian, K., Che, Z., Wang, Z., Yang, X., Su, Y., Lin, X., Song, F., and Zhao, J. (2020). Vindoline inhibits RANKL-induced osteoclastogenesis and prevents ovariectomy-induced bone loss in mice. Front. Pharmacol., 10.10.3389/fphar.2019.01587 ↗
62. Rutaecarpine: A promising cardiovascular protective alkaloid from evodia rutaecarpa (Wu Zhu yu)10.1016/j.phrs.2018.12.019 ↗
63. Ali, D., Okla, M., Abuelreich, S., Vishnubalaji, R., Ditzel, N., Hamam, R., Kowal, J.M., Sayed, A., Aldahmash, A., and Alajez, N.M. (2024). Apigenin and Rutaecarpine reduce the burden of cellular senescence in bone marrow stromal stem cells. Front. Endocrinol., 15.10.3389/fendo.2024.1360054 ↗
64. TGF-b and BMP signaling in osteoblast differentiation and bone formation10.7150/ijbs.2929 ↗
65. Cartilage oligomeric matrix protein enhances osteogenesis by directly binding and activating bone morphogenetic protein-210.1016/j.bone.2013.03.007 ↗
66. Role of TGF-beta signaling in coupling bone remodeling10.1007/978-1-4939-2966-5_18 ↗
67. Rutaecarpine exerted anti-osteroporosis
68. Association between cardiovascular diseases and osteoporosisreappraisal10.1038/bonekey.2012.144 ↗
69. Pharmacological effects of rutaecarpine as a cardiovascular protective agent10.3390/molecules15031873 ↗
70. Vasorelaxant effects of harmine and harmaline extracted from Peganum harmala L. seeds in isolated rat aorta10.1016/j.phrs.2006.04.001 ↗
71. The small molecule harmine is an antidiabetic cell-type-specific regulator of PPARγ expression10.1016/j.cmet.2007.03.010 ↗
72. Pharmacological effects of harmine and its derivatives: A review10.1007/s12272-020-01283-6 ↗
73. Harmine, a beta-carboline alkaloid, inhibits osteoclast differentiation and bone resorption in vitro and in vivo10.1016/j.ejphar.2010.10.048 ↗
74. NFATc1: Functions in osteoclasts10.1016/j.biocel.2009.12.018 ↗
75. Harmine enhances type H vessel formation and prevents bone loss in ovariectomized mice10.7150/thno.22144 ↗
76. Effect of harmane on the convulsive threshold in epilepsy models in mice10.1196/annals.1304.023 ↗
77. Toxicokinetics of tremorogenic natural products, harmane and harmine, in male Sprague-Dawley rats10.1080/152873901753246241 ↗
78. Novel harmine derivatives for tumor targeted therapy10.18632/oncotarget.3276 ↗
79. Harmine targets inhibitor of DNA binding-2 and activator protein-1 to promote preosteoclast PDGF-BB production10.1111/jcmm.16562 ↗
80. Current understanding of RANK signaling in osteoclast differentiation and maturation10.14348/molcells.2017.0225 ↗
81. The small molecule harmine regulates NFATc1 and Id2 expression in osteoclast progenitor cells10.1016/j.bone.2011.04.003 ↗
82. DC-STAMP: A key regulator in osteoclast differentiation10.1002/jcp.25389 ↗
83. Mir, S.A., Padhiary, A., Pati, A., Tete, S.S., Meher, R.K., Baitharu, I., Muhammad, A., and Nayak, B. (2023). Potential phytochemicals as microtubule-disrupting agents in cancer prevention. Recent Frontiers of Phytochemicals, Elsevier.10.1016/B978-0-443-19143-5.00020-7 ↗
84. Yohimbine hydrochloride ameliorates collagen type-II-induced arthritis targeting oxidative stress and inflammatory cytokines in Wistar rats10.1002/tox.22264 ↗
85. Safety of individual medication of Ma Qian Zi (semen strychni) based upon assessment of therapeutic effects of Guo’s therapy against moderate fluorosis of bone10.1016/S0254-6272(12)60007-7 ↗